Thousands of men in England are set to benefit from a new NICE-approved prostate cancer treatment that offers life-extending results with fewer side effects. In this blog, Dr Richard Dune explores the approval of darolutamide combined with androgen deprivation therapy, a milestone that halves the risk of death for men with advanced prostate cancer who cannot tolerate chemotherapy. He examines what this means for patients, professionals, and the wider health system from improving equity and access to embedding new NICE guidance into governance, compliance, and workforce training across the NHS.

Artificial intelligence is no longer on healthcare’s horizon. It is here. In this blog, Dr Richard Dune examines Menlo Ventures’ 2025: The State of AI in Healthcare report and what its findings mean for UK health and social care leaders. He explores how AI adoption has surged across hospitals and life sciences, how governance and workforce readiness must evolve, and why digital maturity will soon define inspection readiness. As the NHS and care sector approach a new digital era, disciplined innovation, ethical oversight, and transparent governance will determine who leads and who lags behind.